Malnutrition and Alcohol in Patients Presenting with Severe Complications of Cirrhosis After Laparoscopic Bariatric Surgery. by Mendoza, Yuly P. et al.
BRIEF COMMUNICATION
Malnutrition and Alcohol in Patients Presenting with Severe
Complications of Cirrhosis After Laparoscopic Bariatric Surgery
Yuly P. Mendoza1,2 & Chiara Becchetti1,2 & Tao Wan2,3 & Philipp Nett1 & Susana G. Rodrigues1,2 &
Jean-François Dufour1,2 & Annalisa Berzigotti1,2
Received: 25 October 2020 /Revised: 14 January 2021 /Accepted: 14 January 2021
# The Author(s) 2021
Abstract
Factors and outcomes associated with decompensation of liver disease and liver failure in obese patients who underwent modern
bariatric surgery are unclear. We present here a cohort of seventeen consecutive patients referred because of decompensation of liver
disease following laparoscopic bariatric surgery. All patients showed signs of malnutrition (sarcopenia in 76.5%). In ten (58.8%),
decompensation was associated with alcohol ingestion, which started after bariatric surgery in six patients. One patient died and three
patients required liver transplantation, in one case preceded by transjugular intrahepatic portosystemic shunt (TIPS). However, thirteen
patients achieved stabilization or full re-compensation with medical therapy and nutritional support. Our cases underline the risk of
alcohol intake andmalnutrition after laparoscopic bariatric surgery as causes of severe liver decompensation and underline the need for
careful interdisciplinary care of these patients after surgery to early identify and treat alcohol misuse, malnutrition, and liver disease.
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Abbreviations
BMI Body mass index
ALT Alanine aminotransferase
AUD Alcohol use disorder
GGT Gamma-glutamyl transpeptidase
INR International normalized ratio
OSA Obstructive sleep apnea




%EWL Percent excess weight loss
%TWL Percent total weight loss
BPD-DS Biliopancreatic diversion with duodenal
switch procedure
RYGB Roux-en-Y-gastric-bypass
NRH Nodular regenerative hyperplasia
HRS Hepatorenal syndrome






TIPS Transjugular Intrahepatic Portosystemic Shunt
OLT Orthotopic liver transplantation
MELD Model for End-stage Liver Disease
ALD Alcohol-related liver disease
AHHS Alcoholic Hepatitis Histologic Score
Introduction
Obesity has grown dramatically in the last 20 years, becoming
rapidly a public health issue. This led to a massive increase in
cases of non-alcoholic fatty liver disease (NAFLD), or as most
recently defined, metabolic associated fatty liver disease
(MAFLD) [1], which can progress to end-stage liver disease
and development of hepatocellular carcinoma. Lifestyle mod-
ifications are the first-line therapy for obesity and NAFLD,
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but only a minority of patients achieve clinically relevant and
durable weight loss. Bariatric surgery is an effective therapeu-
tic approach for morbid obesity and for patients with obesity
presenting metabolic complications and not responding to
lifestyle changes [2].
Bariatric procedures currently used include restrictive
bowel surgery (i.e., laparoscopic adjustable gastric
banding and sleeve gastrectomy), and procedures combin-
ing malabsorption and restriction (i.e., biliopancreatic di-
version (BPD), and Roux-en-Y-gastric-bypass (RYGB)
[2]. Pure malabsorptive procedures, such as jejunoileal
bypass, have been abandoned because of the high long-
term complication rates including liver failure. Rapid
weight loss and severe post-operative malnutrition might
indeed lead to liver disease progression to cirrhosis and its
complications [3–5].
Studies have shown a high prevalence, ranging from 12 to
20% of alcohol use disorder (AUD) after bariatric surgery [6,
7]. However, data describing the features of decompensation
of liver disease after laparoscopic bariatric surgery according
to alcohol consumption are lacking.
This study aimed at depicting the clinical characteristics of
a consecutive cohort of patients who developed liver dysfunc-
tion and clinical decompensation of liver disease after current-
ly practiced techniques of bariatric surgery.
Methods
We retrospectively assessed all patients consecutively ob-
served due to clinical decompensation of liver disease occur-
ring after bariatric surgery at academic center between
February 2014 and February 2020. Patients were followed
until May 2020.
Pre- and post-operative data collected included anthropo-
metric variables, comorbidities, laboratory, radiology results,
nutritional and metabolic complications, and alcohol con-
sumption. The presence and severity of liver disease before
surgery was carefully investigated. We recorded the type of
bariatric surgery and presence and type of intra- and post-
operative complications. In the follow-up, we collected data
on the type of clinical decompensation (ascites, portal hyper-
tensive bleeding, or hepatic encephalopathy) and other com-
plications of cirrhosis (e.g., severe bacterial infections). We
calculated the following since surgery: (a) weight loss in ki-
logram; (b) percent total weight loss (%TWL); and (c) percent
excess weight loss (%EWL).
Outcomes included recovery, further decompensation,
death, or liver transplantation. The study was executed in ac-
cordance with the Helsinki declaration. All patients included
in the present study signed the general consent allowing reuse
of their health-related data. A study-specific informed consent
was not required.
Results
Seventeen patients (64.7% male, median age of 55.2 years
[IQR 49–63]) presented clinical decompensation of liver dis-
ease after laparoscopic bariatric surgery in the study period.
Surgery had been performed in other centers in the majority of
cases (n = 11, 65%). Preoperative body weight and BMI were
127.0 ± 23.2 kg and 42.9 ± 6.3 kg/m2, respectively.
Eleven patients (65%) had received a non-invasive assess-
ment of liver disease before bariatric surgery. Among them,
three patients showed no liver disease, three (18%) had
NAFLD without severe fibrosis and five patients (29%) had
cirrhosis. All patients with cirrhosis were in compensated
stage, Child-Pugh A5-B7 and MELD 6–9 points. In the re-
maining 6 patients, no information regarding a possible pre-
existing liver disease was available (they had been seen and
operated on in other centers).
Among the five patients diagnosed with cirrhosis by non-
invasive tests and clinical findings, one was biopsied before
the surgical intervention, and cirrhosis was confirmed. The other
four received biopsy during bariatric surgery showing bridging
fibrosis and mild steatohepatitis in two, and cirrhosis in two.
One additional patient underwent liver biopsy during surgery
and histology showed nodular regenerative hyperplasia (NRH).
Laparoscopic RYGB was used in eleven cases (65%), lap-
aroscopic sleeve gastrectomy in five (29%), and laparoscopic
gastric banding in one (6%). The latter did not achieve a sat-
isfactory weight loss, and later on, underwent laparoscopic
biliopancreatic diversion with duodenal switch procedure
(BPD-DS). Three patients (18%) developed surgical compli-
cations (anastomotic leak) requiring re-laparoscopy and drain-
age. No surgical mortality was observed. The intervention led
to a significant weight reduction in all, but in two cases. The
median BMI, %EWL, and %TWL at the time of clinical de-
compensation were 25.4 kg/m2 (range16.7–36.4 kg/m2),
96.8% (35–163%), and 36.6% (13–60%), respectively.
Features of Clinical Decompensation of Liver Disease
Clinical decompensation of liver disease developed in a me-
dian of 33 months (IQR 8–73) after surgery. At presentation,
decompensation was severe in 14 cases (82%; median MELD
score 18 points) and mild in 3 (18%; median MELD score 6
points). The characteristics of bariatric surgery, clinical
course, and clinical decompensation in the study population
are shown in Fig. 1 and more in detail in Supplementary
Table 1.
Ten patients (58.8%) presented excessive alcohol con-
sumption associated with AUD at the time of severe decom-
pensation. Among the 10 cases, three patients reported an
alcohol intake before surgery but none of them had a recog-
nized AUD, which they developed after surgery. The remain-
ing six patients started drinking alcohol 1–4 years after
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bariatric surgery. The amount of alcohol consumption varied
between 30 and 400 g/day. As for the cofactors related to
alcohol intake, 50% of patients had been diagnosed with de-
pression. Clinical decompensation was severe in all 10 pa-
tients with alcohol misuse.
In the two patients with alcoholic hepatitis, the Maddrey
discriminant function was 17 and 77. Severe bacterial infec-
tions were present in five patients, with three being critically
ill, requiring intensive care.
As for the nutritional status, thirteen patients (76.5%) re-
ceived a diagnosis of sarcopenia, in two cases associated with
persistent obesity (sarcopenic obesity). The remaining four
(23.5%) were diagnosed with severe malnutrition (cachexia).
Ten patients had a complete nutritional assessment at the time
of decompensation showing low pre-albumin serum levels
0.06 ± 0.05 g/L, as well low albumin 25.5 ± 6 g/L, zinc 8.69
± 2.74 μmol/L, magnesium 0.79 ± 0.28 μmol/L, and selenium
0.72 ± 0.26 μmol/L.
Patients with and without alcohol intake had similar weight
loss (P = 0.823), BMI (P = 0.778), %EWL (P = 0.849), and
%TWL (P = 0.761).
All received a nutritional assessment by nutrition special-
ists, who prescribed oral supplementation targeting 35–
40 kcal/kg/day, as well as protein intake of 1.2–1.5 g/kg/day
by high-protein liquid supplement (protein 10 g/100 ml), plus
substitution of vitamins and/or trace elements. Eight (47%)
patients required further enteral nutrition supplemented
through nasojejunal tube (NJT) for 1 to 4 months, two
(12%) of them had intolerance to NJT and required parenteral
nutrition.
Two patients underwent bariatric re-intervention.
Laparoscopic reversal of bariatric surgery was performed in the
patient who previously underwent BPD-DS. In another patient,
who had undergone RYGB, a proximalization of the lower anas-
tomosis was performed 2 years after the first surgery. Both sur-
gical procedures resulted in improvement of malnutrition and
clinical stabilization of liver disease.
The duration of the first hospitalization was in median of
20 days (IQR 7–28). All patients were maintained on nutri-
tional supplementation and alcohol abstinence.
At the end of follow-up, eleven (65%) patients were alive
without liver transplantation, three (18%) patients underwent
liver transplantation (in one case after TIPS for refractory as-
cites), two patients (12%) are currently on the liver transplan-
tation waiting list in a stable clinical situation and one (6%)
died due to end-stage liver disease (sepsis, ascites, and hepatic
hydrothorax).
The histological findings of one of the described cases who
achieved improvement after enteral nutrition and was success-
fully transplanted are shown in Fig. 2.
Discussion
In the present series, we described the features and outcomes
of patients presenting liver decompensation after bariatric sur-
gery. Many of them presented with very severe liver dysfunc-
tion and complications of portal hypertension, and bacterial
infections were common. Almost two-thirds of patients re-
ported excessive alcohol consumption. Notably, some of them
Fig. 1 Characteristics of bariatric surgery, clinical course, and clinical
decompensation in the study population. RYGB, Roux-en-Y-gastric-
bypass; SG, sleeve gastrectomy; BPD-DS, biliopancreatic diversion
with duodenal switch procedure; HRS, hepatorenal syndrome; SBP,
spontaneous bacterial peritonitis; HE, hepatic encephalopathy; AH,
alcoholic hepatitis
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started drinking alcohol after bariatric surgery (one to 4 years
after).
In our cohort, none of the patients had a recognized AUD
prior to surgery, and patients began misusing alcohol after
bariatric surgery. There is experimental and clinical evidence
suggesting that bariatric surgery increases the risk of alcohol
misuse [6, 8]. Among the mechanisms of “de novo” alcohol
addiction, it has been suggested that after bariatric surgery
patients experience an “addiction transfer” replacing the old
addiction (food) with a new one (alcohol). This could explain
the pattern of “de novo” AUD in our patients. Neuro-
hormonal mechanisms determining changes in reward pro-
cessing and dopamine signaling are involved [9].
Additionally, hormones as ghrelin and glucagon-like pep-
tide-1 (GLP-1), which change after bariatric surgery and play
a role in the gut-liver-brain axis, may modulate the dopamine
reward system, leading to an increased sensitivity to rewards
or craving following bariatric surgery. In this “primed” sys-
tem, alcohol easily becomes an alternative reward to food [8,
9]. Another not exclusive hypothesis is that alcohol intoxica-
tion can take place more quickly with less alcohol and lasts
longer in this situation.
Over one-third (41%) of patients in the present series de-
veloped decompensation of liver disease in the absence of
alcohol consumption. Although it is well established that bar-
iatric surgery is effective in patients with non-alcoholic
steatohepatitis (NASH) and obesity, leading to resolution of
NASH in up to 80–100% and to fibrosis improvement [2],
some reports described that a drastic and rapid weight loss
(over 1.6 kg/week) can worsen the course of liver disease.
Rapid weight loss leads in fact to rapid mobilization of extra-
hepatic fat resulting in increases in free fatty acids and proin-
flammatory cytokines, with worsening of steatohepatitis lob-
ular activity [3, 10]. Mechanisms leading to steatohepatitis in
this clinical scenario are not completely understood. On the
one side, the rapid weight loss after bariatric surgery produces
fast and massive destruction of adipose tissue in visceral and
peripheral deposits, leading to release of free fatty acids (FFA)
in plasma, reaching the liver through the portal vein [5]. It has
also been hypothesized that after bariatric surgery there could
be an alteration in bacterial overgrowth of the excluded small
intestine, promoted by absence of bile acids, decreased gastric
acidity, and dysmotility, which lead to mucosal injury and
increase gut permeability to endotoxins [3].
In our study, five patients presented decompensation of
liver disease after sleeve gastrectomy. Importantly, all had a
diagnosis of compensated cirrhosis prior to bariatric surgery.
Compensated cirrhosis without severe portal hypertension is
Fig. 2 Histology at the time of decompensation showed cirrhosis and
severe macrovesicular steatosis, affecting >95% of hepatocytes,
ballooning of hepatocytes, and lobular inflammation (panels a, b). The
patient was listed for transplantation. He received enteral nutrition and
microelements. His liver function improved (from Child-Pugh 11 to 7
points) during the waiting time. Histology of the explant (panels c, d)
showed cirrhosis without steatosis and mild unspecific porto-septal
inflammation
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not considered a contraindication to sleeve gastrectomy [11],
which has the advantage of interrupting the short gastric veins,
often feeding gastroesophageal varices. However, severe mal-
nutrition, micronutrient deficiencies, and sarcopenia can any-
how occur leading to dramatic deterioration of liver function.
Our findings suggest that strict follow-up of weight loss
and supplementation of vitamins and trace elements should
be performed evenmore carefully in patients with known liver
disease to avoid further progression in those with pre-cirrhotic
stages, and to prevent decompensation in those with cirrhosis.
In addition, alcohol consumption should be specifically
screened and cessation should be recommended. The set of
actions that in our view can be put in place to early detect liver
disease, follow-up its course after bariatric surgery, and poten-
tially avoid clinical decompensation are summarized in
Table 1.
In conclusion, in our cohort, which is the largest so far
reporting on liver decompensation in patients who underwent
modern techniques of bariatric surgery, alcohol use and severe
malnutrition triggered severe episodes of decompensation of
liver disease. Bacterial infections commonly complicated the
course of decompensation, and an appropriate nutritional sup-
plementation led to stabilization and even reversal of the
course of liver disease back to a fully compensated status.
Early detection of malnutrition, prevention, and early recog-
nition of alcohol use disorder, and identification of other risk
Table 1 Suggested actions to identify and follow-up liver disease and to potentially avoid severe decompensation in patients undergoing bariatric
surgery. As shown, this population requires the work of an interdisciplinary team
Aspect to address Before bariatric surgery After bariatric surgery Main responsible
Alcohol misuse • Screen for alcohol use disorder using for
instance Alcohol Use Disorder
Identification Test concise (AUDIT-C)
• Recommend alcohol cessation
• Screen for alcohol use disorder using for
instance AUDIT-C
• Reinforce the need for alcohol use cessation
• Test for AST, ALT and GGT
• If alcohol consumption remains unclear: test for
carbohydrate-deficient transferrin (CDT) or
urinary ethyl glucuronide (uETG)
• All the physicians involved in
the case
• Referral to a psychiatrist if
AUDIT-C positive
• Referral to a hepatologist after
surgery whenever alcohol
consumption or altered liver
tests is detected
Depression • Screen and treat if needed • Screen and treat if needed • Psychologist (screening)







○ Laboratory tests: AST, ALT, ALP,
albumin, bilirubin, INR, platelet count
○ Ultrasound
○ Liver stiffness measurement (transient
elastography; magnetic resonance
elastography)
• In case of possible relevant liver disease:
liver biopsy
• In case of suspected cirrhosis: liver biopsy
using transjugular route and hepatic
venous pressure gradient measurement
• If portal hypertension is confirmed, upper
GI tract endoscopy to rule out varices
• In patients with abnormal liver tests before
surgery or with abnormal results on
intraoperative liver biopsy: regular follow-up
at the liver clinic using the same tests
• Suggested timing after surgery: 3–6 months;
12 months and then every 1–2 years if normal






• Baseline measurement of skeletal muscle
index/psoas area if computerized
tomography is available
• Baseline hand-grip strength test
• Increase physical activity and decrease
sedentary lifestyle.
• Strictly monitor weight loss
• Consider serial hand-grip strength tests to
follow-up physical performance; single slice
CT for muscle mass
• Monitor and treat for micronutrient deficiency
(i.e., zinc, calcium, vitamin D).
If signs of malnutrition (especially in sarcopenic
obese or if too quick weight loss):
• High-protein intake (aim for 1.5-2 g/Kg/day)
• Decrease fasting times—snack/meals every
3–4 h and late evening snack
• Reinforce: increase physical activity and
decrease sedentary lifestyle.
• Endocrinologist expert in
clinical nutrition
• Early referral to hepatologist in
patients with pre-existing liver
disease or alteration of liver
tests
Osteoporosis • Monitor bone mineral density: dual X-ray




factors for liver disease progression and decompensation in
this population should be addressed by future research.
Supplementary Information The online version contains supplementary
material available at https://doi.org/10.1007/s11695-021-05237-9.
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